AR128383A1 - Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos - Google Patents

Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos

Info

Publication number
AR128383A1
AR128383A1 ARP230100212A ARP230100212A AR128383A1 AR 128383 A1 AR128383 A1 AR 128383A1 AR P230100212 A ARP230100212 A AR P230100212A AR P230100212 A ARP230100212 A AR P230100212A AR 128383 A1 AR128383 A1 AR 128383A1
Authority
AR
Argentina
Prior art keywords
c6alkyl
heterocycloalkyl
cycloalkyl
nrcrd
heteroaryl
Prior art date
Application number
ARP230100212A
Other languages
English (en)
Spanish (es)
Inventor
Xin Cheng
Yingtao Liu
Luoheng Qin
Feng Ren
Huaxing Yu
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of AR128383A1 publication Critical patent/AR128383A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP230100212A 2022-01-28 2023-01-30 Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos AR128383A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022074739 2022-01-28
CN2022140318 2022-12-20

Publications (1)

Publication Number Publication Date
AR128383A1 true AR128383A1 (es) 2024-04-24

Family

ID=87470622

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100212A AR128383A1 (es) 2022-01-28 2023-01-30 Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos

Country Status (12)

Country Link
US (1) US20250101019A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469456A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502943A (cg-RX-API-DMAC7.html)
KR (1) KR20240142481A (cg-RX-API-DMAC7.html)
CN (1) CN118871439A (cg-RX-API-DMAC7.html)
AR (1) AR128383A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023213905A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247162A1 (cg-RX-API-DMAC7.html)
IL (1) IL313821A (cg-RX-API-DMAC7.html)
MX (1) MX2024009216A (cg-RX-API-DMAC7.html)
TW (1) TW202340190A (cg-RX-API-DMAC7.html)
WO (1) WO2023143520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074128A1 (en) * 2022-10-08 2024-04-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025007955A1 (en) * 2023-07-06 2025-01-09 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) inhibitor combinations and uses thereof
CN121969621A (zh) * 2023-08-02 2026-05-01 英矽智能科技知识产权有限公司 外核苷酸焦磷酸酶-磷酸二酯酶1 (enpp1)抑制剂的结晶形式及其用途
WO2025026377A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912874A1 (en) * 1990-08-15 1992-02-26 British Bio Technology Compounds
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
CA2672327A1 (en) * 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
US20160222014A1 (en) * 2013-09-10 2016-08-04 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2019023635A1 (en) * 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
ES2960987T3 (es) * 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
WO2021061803A1 (en) * 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CA3204409C (en) * 2021-01-29 2026-04-28 Txinno Bioscience Inc. Benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof

Also Published As

Publication number Publication date
IL313821A (en) 2024-08-01
EP4469456A1 (en) 2024-12-04
KR20240142481A (ko) 2024-09-30
CN118871439A (zh) 2024-10-29
TW202340190A (zh) 2023-10-16
WO2023143520A1 (en) 2023-08-03
US20250101019A1 (en) 2025-03-27
JP2025502943A (ja) 2025-01-30
CA3247162A1 (en) 2023-08-03
AU2023213905A1 (en) 2024-07-11
MX2024009216A (es) 2024-08-06
EP4469456A4 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
AR128668A1 (es) INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS
AR128669A1 (es) INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS
AR127500A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
AR124483A2 (es) Compuestos heterocíclicos útiles como inhibidores de pdk1
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR092536A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR117264A1 (es) Esteroides neuroactivos y métodos para su uso
AR089019A1 (es) Derivados modificados de 4-fenil-piridina
AR068109A1 (es) Derivados tetraciclicos de indol y una composicion farmaceutica
AR117616A1 (es) Compuestos anti-vih
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
AR121777A1 (es) Derivados de diamina macrocíclica como inhibidores de ent para el tratamiento de cánceres, y combinación de estos con antagonistas del receptor de adenosina
AR094816A2 (es) Compuestos antivirales
AR110298A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR120652A1 (es) Antagonistas de sstr5
AR108926A1 (es) Moduladores de cot y sus métodos de uso
AR068106A1 (es) Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR115033A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros compuestos relacionados, como inhibidores del complemento
AR064429A1 (es) Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales.
AR119305A1 (es) Composiciones y métodos para el tratamiento de los trastornos del snc
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
AR088246A1 (es) Derivados de etinilo
AR117472A1 (es) Inhibidores de tienopiridina de ripk2